Xeris Biopharma Holdings (XERS) Intangibles (2021 - 2026)

Xeris Biopharma Holdings' Intangibles history runs 6 years deep, the most recent figure standing at $85.4 million for Q1 2026.

• Quarterly Intangibles fell 11.27% year-over-year to $85.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.4 million (down 11.27% YoY) and the FY2025 annual result came in at $88.1 million, down 10.96% from the prior year.
• Intangibles was $85.4 million for Q1 2026 at Xeris Biopharma Holdings, down from $88.1 million in the prior quarter.
• Across five years, Intangibles topped out at $128.7 million in Q1 2022 and bottomed at $85.4 million in Q1 2026.
• A 5-year average of $107.1 million and a median of $107.1 million in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2022 — Intangibles dropped 8.25% — and 2026, when it fell 11.27%.
• Xeris Biopharma Holdings' Intangibles stood at $120.6 million in 2022, then retreated by 8.99% to $109.8 million in 2023, then dropped by 9.88% to $98.9 million in 2024, then dropped by 10.96% to $88.1 million in 2025, then declined by 3.08% to $85.4 million in 2026.
• Business Quant data shows XERS's Intangibles at $85.4 million in Q1 2026, $88.1 million in Q4 2025, and $90.8 million in Q3 2025.